Salvo Health raises $8.5 million

New York-based Salvo Health has raised an $8.5 million Series A round led by ManchesterStory, City Light Capital, and Threshold Ventures. The round brings Salvo’s total equity raised to $21.6 million.

Founded in 2021, the company provides a hybrid care platform for gastrointestinal providers, combining in-clinic services with AI-supported, continuous care.

According to the press release, Salvo ended 2025 with 800% YoY growth in both patients and revenue, and enterprise agreements with GI practices grew more than 1,000%. Salvo has signed agreements with 801 gastroenterologists, representing about 16% of independent GIs in the US. Its enterprise customers include three of the four largest GI practices nationwide, collectively serving more than 1.1 million patients annually across ten states.

“We invested in Salvo to expand access to ‘whole person’ care to communities across the country where there can be a shortage of GI providers and obstacles to finding world-class multidisciplinary, team-based care. Salvo is allowing community GI practices to build ‘Center of Excellence’ care for the 100 million Americans who suffer from chronic GI conditions such as IBD, IBS, GERD, celiac, and gastroparesis, as well as metabolic conditions such as MASLD and general obesity.” – Matt Kinley, Founding Partner of venture capital firm ManchesterStory.

“We see trusted community GI providers as an under-leveraged channel to deliver comprehensive follow-on care. That is not just for GI conditions but also for metabolic syndrome and obesity, conditions that affect 100 million Americans for which Salvo has proven outcomes.” – Josh Cohen, Managing Partner at City Light Capital.

The company plans to use the proceeds to expand its engineering team with a focus on AI development and to scale national hiring of registered dietitians, behavioral health professionals, and nurses.